Oncotelic Therapeutics Inc. is advancing nanoparticle-based drug delivery strategies through its joint venture entity, positioning the company at the forefront of pharmaceutical innovation that applies ultra-small carrier technologies to enhance existing cancer therapies. The company is pioneering how nanotechnology can improve bioavailability, precision targeting and therapeutic performance of anticancer compounds, with advantages that some experts believe may be as transformative for drug delivery as monoclonal antibodies were for biologics.
The company is now preparing its first-in-human study of an intravenous Everolimus nanoformulation, designated Sapu-003, that it codevelops via its subsidiary and partner Sapu Nano. According to the company, Sapu-003 is designed to overcome the absorption and tumor-penetration limits of conventional oral Everolimus by delivering full bioavailability via intravenous nanoparticle delivery. This approach could potentially address significant limitations in current cancer treatment regimens where drug absorption and distribution to tumor sites remain challenging.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products, with a mission to address high-unmet-need cancers and rare pediatric indications. The company benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures.
Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu’s leadership that is advancing its own pipeline of drug candidates that complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics. The company’s Deciparticle platform represents its core nanoparticle delivery technology that enables these advanced formulations. The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC.
The advancement of nanoparticle drug delivery systems represents a significant shift in pharmaceutical development, with potential implications for improving treatment efficacy while reducing side effects. By enhancing how existing drugs reach their targets, companies like Oncotelic could potentially extend the therapeutic window of approved medications and improve outcomes for cancer patients. The upcoming first-in-human study will provide crucial data on the safety and preliminary efficacy of this novel delivery approach for a widely used cancer medication.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Oncotelic Therapeutics Advances Nanoparticle Drug Delivery Toward First-in-Human Study.